XNAS
QLGN
Market cap2mUSD
Jul 14, Last price
3.69USD
1D
7.89%
1Q
11.82%
Jan 2017
-99.95%
IPO
-99.97%
Name
Qualigen Therapeutics Inc
Chart & Performance
Profile
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2020‑03 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 5,205 4.44% | 4,984 -11.85% | |||||||
Cost of revenue | 16,510 | 22,926 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (11,305) | (17,942) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (5) | (265) | |||||||
Tax Rate | |||||||||
NOPAT | (11,300) | (17,677) | |||||||
Net income | (13,417) -36.21% | (21,035) 17.53% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 7 | ||||||||
BB yield | -0.13% | ||||||||
Debt | |||||||||
Debt current | 1,299 | 1,406 | |||||||
Long-term debt | 2,999 | ||||||||
Deferred revenue | 49 | ||||||||
Other long-term liabilities | |||||||||
Net debt | 897 | (2,635) | |||||||
Cash flow | |||||||||
Cash from operating activities | (10,304) | (13,248) | |||||||
CAPEX | (319) | ||||||||
Cash from investing activities | 4,216 | (184) | |||||||
Cash from financing activities | (550) | 2,911 | |||||||
FCF | (7,862) | (17,595) | |||||||
Balance | |||||||||
Cash | 402 | 7,034 | |||||||
Long term investments | 6 | ||||||||
Excess cash | 142 | 6,791 | |||||||
Stockholders' equity | (116,759) | (101,761) | |||||||
Invested Capital | 115,955 | 113,253 | |||||||
ROIC | |||||||||
ROCE | 1,405.48% | ||||||||
EV | |||||||||
Common stock shares outstanding | 5,073 | 3,840 | |||||||
Price | 0.55 -57.33% | 1.29 -87.95% | |||||||
Market cap | 2,790 -43.64% | 4,950 -84.23% | |||||||
EV | 3,687 | 3,846 | |||||||
EBITDA | (11,300) | (17,567) | |||||||
EV/EBITDA | |||||||||
Interest | 1,525 | 27 | |||||||
Interest/NOPBT |